Company intelligence / Profile preview

AzarGen Biotechnologies

Stellenbosch, Western Cape, South Africa

Ownership: Private
Development stage: Other

Overview

AzarGen Biotechnologies is advancing a pipeline led by recombinant human surfactant protein-B (AZsurf™) for respiratory diseases through preclinical studies, and a plant-made biosimilar of rituximab (AZ2000™) for autoimmune diseases and cancer is being developed in collaboration with iBio; no clinical trial results are reported as of October 2025[1][12][5].

Therapeutic areas: OncologyPulmonologyImmunology
Modalities: Recombinant proteinMonoclonal antibody
Industry: Biotech

Partnerships

iBio (manufacturing and process development for plant-made rituximab[2][5][12])Industrial Development Corporation, South Africa (funding support[1][6])

Beyond the preview

Go deeper on AzarGen Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AzarGen Biotechnologies.

Explore the full profile